key: cord-0797067-wsdfpnhv
authors: Li, Yang; Xiao, Yushuo; Chen, Yuchen; Huang, Kun
title: Nano-based approaches in the development of antiviral agents and vaccines
date: 2020-11-12
journal: Life Sci
DOI: 10.1016/j.lfs.2020.118761
sha: 33eba413ed622066a26e6e5e8eee6042a435d2b3
doc_id: 797067
cord_uid: wsdfpnhv

Outbreaks and the rapid transmission of viruses, such as coronaviruses and influenza viruses, are serious threats to human health. A major challenge in combating infectious diseases caused by viruses is the lack of effective methods for prevention and treatment. Nanotechnology has provided a basis for the development of novel antiviral strategies. Owing to their large modifiable surfaces that can be functionalized with multiple molecules to realize sophisticated designs, nanomaterials have been developed as nanodrugs, nanocarriers, and nano-based vaccines to effectively induce sufficient immunologic memory. From this perspective, we introduce various nanomaterials with diverse antiviral mechanisms and summarize how nano-based antiviral agents protect against viral infection at the molecular, cellular, and organismal levels. We summarize the applications of nanomaterials for defense against emerging viruses by trapping and inactivating viruses and inhibiting viral entry and replication. We also discuss recent progress in nano-based vaccines with a focus on the mechanisms by which nanomaterials contribute to immunogenicity. We further describe how nanotechnology may improve vaccine efficacy by delivering large amounts of antigens to target immune cells and enhancing the immune response by mimicking viral structures and activating dendritic cells. Finally, we provide an overview of future prospects for nano-based antiviral agents and vaccines.

A virus particle is made up of genetic material and a capsid (Fig. 1A) . Housed inside the protein-based capsid, the viral genome consists of single-stranded or double-stranded DNA or RNA in linear or circular form. Some viruses, such as human immunodeficiency virus and coronaviruses, have viral envelopes covering capsids. Typically derived from host cell membranes, the envelopes are composed of phospholipids and proteins and may include viral glycoproteins. Infectious diseases caused by viruses have long been serious threats to global public health [1, 2] ; for example, smallpox and yellow fever have resulted in millions of deaths. In recent years, public health crises have emerged due to epidemics and pandemics of new viruses, including SARS-CoV, MERS-CoV, and H7N9 [3, 4] . The recent pandemic of COVID-19 caused by SARS-CoV-2 has become a global health crisis [5, 6] . The lack of effective treatments remains a primary challenge in the fight against emerging viral threats [7, 8] .

The majority of available antiviral agents are synthetic agents, such as nucleoside analogues that prevent viral genome replication and protease inhibitors that selectively bind to viral proteases and block proteolytic cleavage of viral protein precursors [9] [10] [11] .

contact with viruses and contribute to multiple antiviral effects, such as the inactivation of viruses and blocking viruses from entering host cells [14, 15] .

Historically, vaccines have been vital against smallpox, polio, hepatitis A, and papilloma [16] [17] [18] . However, conventional vaccines are not applicable to some viral infections for two key reasons. First, some viruses are difficult to produce in vitro, which is required for the development of vaccines composed of inactive or attenuated viruses. Second, although vaccines carrying peptide antigens or mRNAs encoding antigens are an alternative, they are limited by low stability and degradation in vivo. Nanomaterials can as act carriers to protect antigens from degradation and improve immune responses, which in turn improves the effectiveness of nanovaccines. Since the first nanovaccine against hepatitis B virus (HBV) was licensed in 1986, nanotechnology has been applied to develop vaccines against human papillomaviruses (HPV) and hepatitis E virus (HEV), and positive preclinical outcomes have been obtained for HIV and respiratory viruses [19] [20] [21] . In light of emerging viruses, such as SARS-CoV-2, nano-based vaccines have received substantial attention [22] .

In this review, we focus on nano-based antiviral agents and vaccines, which are among the most promising approaches for countering outbreaks of emerging viral infections. To provide insight into the use of nanotechnology to manage viral threats, the antiviral mechanisms of nanomaterials as well as recent progress in the development of nano-based vaccines are summarized. Table 1 ) [26, 27] .

To invade, a virus first attaches itself to the membrane of host cells. This behavior is the basis for broad-spectrum anti-infection nanomaterials based on cell membrane properties, known as nanodecoys. The surface of nanodecoys may be derived from cell membranes, providing cell-surface receptors that are recognized by and trap the virus [28] . Indeed, vesicles derived from CD4 + T cell membranes show effective attachment by HIV-1, thereby preventing HIV-1 from binding to and entering healthy CD4 + T cells [29] .

Another artificially engineered membrane-derived vesicle in which the surface is coated with a human sodium taurocholate co-transporting polypeptide effectively blocks HBV infection, spread, and replication in a mouse model [30] .

However, cell membrane-derived vesicles are prone to membrane fusion due to the fluid-filled vesicles and cell membranes, thus generating a risk that vesicles bring envelope that targets CD4 + cells, is critical for the binding of HIV to CD4 + T cells [37] .

Two anti-HIV-1 nanomaterials, gold nanoparticles (AuNPs) encapsulated by polyethylene glycol and silicon nanoparticles (SiNPs) modified with -OH and -NH 2 groups, function by blocking gp120 on the HIV-1 surface [38, 39] . Silver nanoparticles (AgNPs) are able to bind to multiple molecules and have broad-spectrum antiviral effects by inhibiting viral entry. For example, commercially available AgNPs show a strong effect against HIV-1 by interacting with viral gp120 in both cell-free and cell-attached viruses, thus impeding viral binding and entry [40] . AgNPs also hinder the attachment of Avian influenza A virus H7N3 to host cells by blocking influenza hemagglutinin, which plays a critical role in cell entry [41] . Moreover, AgNPs block the entry of herpes simplex virus (HSV)-1, HSV-2, and human parainfluenza virus (HPIV)-3 by interacting with the sulfhydryl group on viral glycoproteins [42, 43] . In addition to nanoparticles (NPs), dendritic polyglycerol sulfate-based nanogels that mimic the cellular membrane heparan sulfate can actively interact with viral glycoproteins, shield virus surfaces, and efficiently block HSV-1 infection [15] .

Modifications to nanomaterials promote their ability to block viral surface proteins.

AgNPs modified with TA have an increased affinity for viral glycoproteins and reduce HSV-2 infectivity by blocking viral attachment, penetration, and spread [44] . Similar inhibitory effects against HSV-1 and HSV-2 entry have been observed using SiNPs modified with glycosaminoglycans [45] , which bind to the "repeat structure" of viral glycoproteins and amyloids [46] . Polyquaternary phosphonium oligochitosan 

Nanomaterials can inhibit viral replication by interacting with the viral protein/genome or inducing a suppressive environment for intracellular viral replication. AuNPs arrest nucleocapsid, and p6 gag proteins required for a functional virus, thereby hindering viral replication [56] . AgNPs also inhibit the replication of dsRNA viruses and Peste des petits ruminants virus (PPRV) by interacting with the viral genome or core proteins related to RNA synthesis [57, 58] .

In addition to direct contact with the viral protein/genome, nanomaterials can also inhibit viral replication by producing an unfavorable intracellular environment for viral replication. Carbon dots established from PEG-diamine and ascorbic acid induce interferon-α (IFN-α) production and the expression of IFN-stimulating genes in host cells, resulting in powerful antiviral responses and the inhibition of the replication of pseudorabies virus (PRV) and porcine reproductive and respiratory syndrome virus (PRRS) [59] . As an organic nanomaterial, poly(aniline-co-pyrrole) polymerized nanoregulators (PASomes) control intracellular reactive oxygen species (ROS) levels in vitro to inhibit viral replication and cell death [60] . Since certain viruses can hijack host cell pathways to cause the biphasic activation of the MEK/ERK cascade, which improves viral replication [61] , investigations of the precise regulation of the intracellular response to viral infection are still warranted when designing antiviral agents.

Nanomaterials, such as Ag, Ti, and carbon-based nanomaterials, directly contact viruses and induce viral inactivation by different mechanisms depending on the nanomaterial and virus. The destruction of the viral envelope by photocatalytic oxidation or physical J o u r n a l P r e -p r o o f damage is a common mechanism by which nanomaterials induce the inactivation of viruses with envelopes. A multi-walled carbon nanotube attached to photoactivating protoporphyrin IX interacts with and destabilizes the envelope of influenza virus H3N2 by ROS [62] . Another interesting viral inactivation effect was observed using negatively charged graphene oxide (GO), which interacts with the viral envelope by electrostatic interactions and damages the viral envelope via its sharp-edged single-layer structure [63] .

There are also envelope-binding NPs that cause the destruction and disintegration of viruses by unknown mechanisms, including TiO 2 NPs on H 3 N 2 [64] . Additionally, GO-conjugated AgNPs bind to the lipid tails of feline coronavirus (FCoV) and lead to envelop rupture [65] .

Similar to the envelope-rupture effect, some nanomaterials inactivate viruses by destroying the viral capsid via photocatalytic oxidation and protein degradation. TiO 2 NPs interact with viral capsid proteins and inactivate viruses, such as influenza virus and MS2 bacteriophage, via photocatalytic oxidation in which catalytic inactivation is mediated by hydroxide radicals [14, 66, 67] . AgNP-MHCs (aminopropyl-functionalized

Nano-based vaccines, or nanovaccines, are vaccines that use NPs as carriers. A variety of NPs could be used for nanovaccine construction, such as protein/peptide self-assembled virus-like particles (VLPs), inorganic-based NP-like AuNPs, and organic-based NPs, such as lipid nanoparticles (LNPs) ( Table 2 ). Nanovaccines improve antigen bioavailability in vivo and influence the innate and adaptive immune responses, including the generation of memory cells, which are essential for the efficacy of a vaccine ( Fig. 2) [71-75].

Immunological benefits of nano-based vaccines result from a combination of the following properties: the ability to mimic viruses in terms of size and structure (pathogen-mimicking VLPs), the ability to deliver viral antigens to target immune cells, the ability to activate DCs, and the ability to efficiently activate B cells and induce humoral immune responses (Fig. 3 ).

VLPs are self-assembled noninfectious NPs that lack genetic materials [76, 77] . They could be formed by antigen peptides or self-assembled proteins, such as ferritin. Antigens on VLPs optimize the activation of specific immune responses, including humoral and cellular immunity [78] . With innate viral structures, VLP vaccines benefit from their J o u r n a l P r e -p r o o f ability to interact with the immune system without causing infections and inducing an immune response without an adjuvant, which improves the immune response of vaccines [79, 80] .

VLPs are the most widely applied nanosystem for antiviral vaccines. Currently available HPV vaccines, such as Gardasil, Gardasil 9, and Cervarix, which effectively protect women from HPV infection, are all nano-based VLP vaccines [81] . A VLP vaccine against HEV, Hecolin, is also commercially available [82] .

The targeted delivery of antigen peptides or proteins to specific tissues is a major advantage of nanovaccines [19, 20, 83] . Moreover, since unprotected peptide antigens are unstable in vivo, nanomaterials provide protection against enzymatic degradation [84] [85] [86] .

Furthermore, NPs may improve antigen transport to the lymphatic system [87] [88] [89] , since lymphatic gaps preferentially allow the passage of molecules between 20 and 200 nm [90] . For example, in a mouse intradermal injection study, ultra-small nanoparticles (25 nm) are efficiently transported into the lymphatic system and target a subset of lymph DCs [91] .

The presentation of exogenous antigens on MHC class I molecules by DCs, known as cross-presentation, is essential for the initiation of the CD8 + T cell response [92] .

Conventional antigen peptide-based vaccines are insufficient for cross-presentation, while nanovaccines can activate DCs by adequate cross-presentation [93, 94] . In addition, nanovaccines have also been reported to enhance the MHC II pathway, which passes antigens to CD4 + T cells, leading to improved B cell activation [95] .

Pattern-recognition receptors (PRRs), such as Toll-like receptors, NOD-like receptors, and RIG-I-like receptors, are expressed on DCs and associated with the recognition of pathogen-associated molecular patterns, DC maturation, and the expression of type I IFN, an antiviral inflammatory cytokine [96] [97] [98] [99] . Thus, PRR agonists have been used in nanovaccines as adjuvants, which bind to PRRs and upregulate related pathways, thus activating DCs and enhancing immune responses [100, 101] .

Antibody titers are closely correlated with vaccine effectiveness. Nanovaccines have been shown to induce high antibody titers [102] [103] [104] [105] , probably due to their superiority in target delivery and DC activation as well as the capacity to carry large amounts of antigens [106] . Nanovaccines can be constructed to carry large quantities of peptides or protein antigens; this provides a high concentration of antigens for efficient B cell receptor (BCR) signaling, consequently improving the B cell response and antibody production (Fig. 3) [107]. For example, despite the relatively low immunogenicity of HIV-1 envelope (Env) trimer antigens, the enhanced induction of neutralizing antibodies against HIV-1 has been observed in animals immunized with nanovaccines loaded with these antigens [108] .

J o u r n a l P r e -p r o o f

Nanotechnology is increasingly used for the development of antiviral vaccines. Since a nanovaccine against hepatitis B virus (HBV) was first licensed in 1986, this approach has been used to develop vaccines against HPV and HEV, which have achieved positive preclinical outcomes against viruses, such as HIV and respiratory viruses [19] [20] [21] 109 ].

Vaccines for coronaviruses usually use viral surface spike proteins as antigens, which play a critical role in viral attachment to host cells. A VLP vaccine was produced by the co-recombination of SARS-CoV spike protein and the influenza M1 protein; the VLPs induced a strong immune response and had a protective effect in mice [110] . Another AuNP-based vaccine increased the IgG response from B cells by stimulating macrophages, DCs, and lymphocytes, resulting in the induction of proinflammatory cytokine production [111] .

Positive results have also been achieved in the development of NP-based vaccines for MERS-CoV. A ferritin fusion protein with a viral antigen receptor-binding domain can self-assemble into VLPs, which stimulate CD4 + T cells and IFN/TNF responses. Loaded with a STING (stimulator of interferon genes) agonist as an adjuvant to increase DC activation, hollow polymeric NPs were able to stimulate remarkable humoral responses and IgG2a production. Another nanovaccine formed by the full-length spike protein of J o u r n a l P r e -p r o o f MERS-CoV also stimulated significant titers of neutralizing antibodies [112] [113] [114] .

In terms of SARS-CoV-2, mRNA-based nanovaccines have been developed using LNPs as carriers to protect mRNAs from degradation by extracellular RNases and to efficiently deliver mRNAs to immune cells and thereby trigger the translation of antigen proteins [115] [116] [117] [118] . Moreover, the sustained release of mRNAs from LNPs leads to continuous protein translation, stimulating the production of high antibody titers and enhanced B cell and T cell immune responses [119] . There are currently five LNP-encapsulated mRNA vaccines under clinical trials (NCT04470427, NCT04368728, NCT04449276, ISRCTN1707269, and NCT04480957) using mRNAs encoding the full-length spike protein of SARS-CoV-2 or spike protein fragments as antigens. One of these mRNA-based LNP vaccines was reported to induce a strong immune response in participants, resulting in the production of high titers of neutralizing antibodies against SARS-CoV-2 [22] , and is now under a phase III trial (NCT04470427) [120] .

HIV is an RNA virus; owing to its high mutation frequency, it is challenging to develop a successful vaccine capable of inducing antibodies against diverse strains [121] [122] [123] [124] . A vaccine assembled from HIV Env trimers from various HIV-1 strains stimulated a broad spectrum of neutralizing antibodies (bNAs) against diverse virus strains [108] . Another Env gp120/gp41 trimer-assembled VLP had similar effects [125, 126] . In mice immunized with HIV Env-based polystyrene NPs, which enhance the activation of CD4 +

antibody-secreting cells were found [127] .

A conventional method to protect against influenza virus is vaccination with a trivalent inactivated influenza vaccine (TIV), including two influenza A viruses and one influenza B virus [128] . However, the available TIV formulation is insufficient for mucosal protection, since TIV is not able to induce sufficient IgA, which is distributed on and protects the mucous membranes of the lungs, sinuses, stomach, and intestines [129, 130] .

Successful nasal immunization was achieved in rabbits immunized with whole influenza virus incorporated into a mucoadhesive carrier chitosan; significant levels of anti-hemagglutinin antibody, local anti-influenza virus IgA, systemic IL-2, and IFN-γ were detected in the serum [131] . Another successful nanovaccine was established by adsorbing both inactivated swine influenza virus antigens and TLR3 agonist poly(I:C) onto cationic alpha-D-glucan NPs [132] . The poly(I:C) adjuvant promoted cytokine production; thus, the nanovaccine induced high levels of virus-neutralizing antibodies in bronchoalveolar lavage fluid and IgA antibodies in the nasal passage and lungs of immunized pigs [132] . Beneficial effects of mucosal immunization with NPs were also observed in chickens immunized via the aerosol route. In this study, poly(lactic-co-glycolic acid) (PLGA) loaded with formalin-inactivated H9N2 virus and J o u r n a l P r e -p r o o f CpG generated a significantly stronger antibody response than that generated by non-encapsulated antigens [133] .

Foot-and-mouth disease (FMD) caused by FMDV, a picornavirus, and the prototypic member of the genus Aphthovirus, is a serious health threat, especially in children [134] .

Traditional vaccines against FMDV require multiple injections to confer sufficient immunity. The use of calcium mineralization to fabricate FMDV VLPs is a simple improvement. Such bio-mineralization improves the thermal stability and storage time of the vaccine and effectively activates DCs to express high levels of surface MHC-II, costimulatory molecules, and proinflammatory cytokines, leading to enhanced immune responses [95] . Another vaccine combines the polyelectrolyte complexation of chitosan and heparin to co-encapsulate the VP1 protein antigen from enterovirus 71, which causes FMD, with TNFα or CpG as adjuvants [135] . This nanovaccine induced strong immune activation toward antibody production and conferred effective protection against a lethal virus challenge in mice. Moreover, it elicited strong IgA titers, which may provide unique advantages for mucosal protection [135] . Another FMDV VLP loaded in a hollow mesoporous silica nanoparticle (HMSN) induced persistent humoral immunity with high antibody titers for longer than 3 months in guinea pigs, accompanied by improved T cell proliferation and IFN-γ production [136] .

The applications of a major Dengue virus (DENV) immunogen, the E protein, in NPs has produced promising results in mouse models. Engineered bacterial membrane vesicles carrying dengue EDIII antigens effectively evoke humoral immune responses and confer effective protection against DENV-2 infection in mice [137] . Compared with antigens for free DENV-2 E protein, the combination of PLGA NP with E protein increased the anti-E IgG titer and improved neutralizing antibodies in mice [138] . Another NP vaccine composed of chitosan with UV-inactivated DENV-2 induced high IgG levels in mice [139, 140] . An NP nasal vaccine based on chitosan has been tested for the delivery of DENV-3 E protein; it was taken up efficiently by nasal epithelial cells, resulting in increased IL-1β, IL-6, and TNF-α secretion [141] .

Nano-based vaccines have also been developed against other viruses, such as hepatitis C virus (HCV), respiratory syncytial virus (RSV), and West Nile virus (WNV). HCV and WNV nanovaccines have successfully stimulated the immune system to produce antibodies and protect animal models from viral infection in preclinical tests [142, 143] .

Vaccines against RSV have been successful in clinical trials (NCT02624947).

Pandemics and epidemics caused by newly emerged viruses, such as SARS-CoV-2, have J o u r n a l P r e -p r o o f revealed the urgent need to develop antiviral agents that function by novel mechanisms and various routes to combat viruses. Nanotechnology has a tremendous opportunity to improve the prevention and treatment of viral diseases for several reasons. First, nanomaterials can be flexibly functionalized with multiple molecules to realize sophisticated antiviral designs. Second, nanomaterials inhibit virus infection from multiple directions based on various antiviral effects (Fig. 1B) . Third, nanomaterials have broad-spectrum antiviral properties due to common underlying mechanisms. For example, nanodecoys trap diverse viruses prone to attachment to cell membrane-derived or -coated structures [28] .

Nanomaterials have many advantages for the development of antiviral drugs. Compared with antibodies, nanomaterials are relatively easy to produce and thus more affordable.

Moreover, rational design could be introduced to improve clinical effects [144, 145] . Nanomaterials could also be designed to target viral factors, such as antibodies. For example, AuNPs and AgNPs could be designed to target gp120 in HIV and hemagglutinin in influenza virus, respectively [38, 41] . Moreover, the combined use of nanomaterials with other antiviral drugs may resulted in enhanced antiviral effects. For example, carbon dots can be used to induce IFN-α production and IFN-stimulating gene expression in host cells, which may increase the inhibitory effects of synthetic agents, such as nucleosides, on viral replication [59] .

Va ccination is an efficient intervention to protect against viral infection. Nano-based vaccines have many clinical advantages over conventional vaccines, including their J o u r n a l P r e -p r o o f ability to transport high concentrations of antigens to B cells and to induce abundant immune responses (Fig. 3) . Although many nano-based vaccines remain in pre-clinical stages, progress in the application of nanotechnology to vaccines against viruses, such as coronaviruses, HIV, and FMDV, suggests that this approach is promising for the development of vaccines.

Finally, although they have various advantages over other approaches, the safety of antiviral nanomaterials needs to be carefully evaluated before the clinical translation of novel nanotechnologies. Given the lack of knowledge about the risks of exposure to nanomaterials in humans, in-depth studies of nanotoxicity, especially under long-term observation, are needed [146] . Further investigations of the distribution, accumulation, and clearance of nanomaterials in the human body are also warranted. Fortunately, nano-based anti-cancer candidates are already undergoing clinical trials (www.cancer.gov/nano/cancer-nanotechnology) [147] , which will provide insight into their safety in humans and extend their use as antiviral agents and vaccines.

List of chemical compounds: polyethylene glycol; polyglycerol sulfate; heparan sulfate; tannic acid; glycosaminoglycans; poly(aniline-co-pyrrole); protoporphyrin IX; ascorbic acid; 2,2'-(ethylenedioxy)bis(ethylamine); 3-ethoxypropylamine J o u r n a l P r e -p r o o f

There are no conflicts to declare. 

Polyethylene glycol encapsulated AuNPs HIV-1 Blocking gp120 attachment with CD4 + cells [38] SiNPs with -OH and -NH 2 groups HIV-1 Blocking gp120 attachment with CD4 + cells [39] AgNPs HIV-1 Interacting with viral gp120 in both cell-free and cell-associated virus [40] J o u r n a l P r e -p r o o f processing through a protease-independent mechanism [56] AgNPs Peste des petits ruminants' virus (PPRV)

Interacting with virion surface and core protein, impairing viral replication and entry [57] AgNPs dsRNA viruses Interacting with viral genome [58] Carbon dots PRV, porcine reproductive and respiratory syndrome virus

Inducing antiviral response of interferon-α (IFN-α) production and the expression of IFN-stimulating genes (ISGs) in host cells [59] Poly(aniline-co-pyrrole) polymerized nanoregulators (PASomes) J o u r n a l P r e -p r o o f 

Changing patterns of infectious disease

Progress in global surveillance and response capacity 10 years after severe acute respiratory syndrome

Copper and iron ions accelerate the prion-like propagation of alpha-synuclein: A vicious cycle in Parkinson's disease

Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study

COVID-19 & Chronic Renal Disease: J o u r n a l P r e -p r o o f Clinical characteristics & prognosis

Development of a preventive vaccine for Ebola virus infection in primates

Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys

Protease inhibitors as antiviral agents

Therapeutic strategies to target the Ebola virus life cycle

Clinical significance of chemokine receptor antagonists

Influenza A Virus Antibodies with Antibody-Dependent Cellular Cytotoxicity Function

Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2

Photocatalytic inactivation of influenza virus by titanium dioxide thin film

Multivalent Flexible Nanogels Exhibit Broad-Spectrum Antiviral Activity by Blocking Virus Entry

The problems with polio: toward eradication

Immunogenicity and estimation of antibody persistence following vaccination with an inactivated virosomal hepatitis A vaccine in adults: A 20-year follow-up study

The impact of immunization programs on 10 vaccine preventable diseases in Italy

Nanovaccines: recent developments in vaccination

Nanotechnology in vaccine delivery

Synthetic Biodegradable Microparticle and Nanoparticle Vaccines against the Respiratory Syncytial Virus. Vaccines (Basel)

An mRNA Vaccine against SARS-CoV-2 -Preliminary Report

Autophagy and Viral Infection

Differential Features of Fusion Activation within the Paramyxoviridae

Recent advancements in biocompatible inorganic nanoparticles towards biomedical applications

Actively Targeted Deep Tissue Imaging and Photothermal-Chemo Therapy of Breast Cancer by Antibody-Functionalized Drug-Loaded X-Ray-Responsive Bismuth Sulfide@Mesoporous Silica Core-Shell Nanoparticles

Cell-Membrane-Mimicking Nanodecoys against Infectious Diseases

Nef neutralizes the ability of exosomes from CD4+ T cells to act as decoys during HIV-1 infection

Bioinspired Artificial Nanodecoys for Hepatitis B Virus

Binding and Fusion of Extracellular Vesicles to the Plasma Membrane of Their Cell Targets

T-Cell-Mimicking Nanoparticles Can Neutralize HIV Infectivity

Inhibition of Pathogen Adhesion by Bacterial Outer Membrane-Coated Nanoparticles

A Biomimetic Nanodecoy Traps Zika Virus To Prevent Viral Infection and Fetal Microcephaly Development

Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform

Cellular Nanosponges Inhibit SARS-CoV-2 Infectivity

HIV: cell binding and entry. Cold Spring Harb Perspect Med

Gold Nanoparticles as an HIV Entry Inhibitor

Viral Inhibition Mechanism Mediated by Surface-Modified Silica Nanoparticles

Mode of antiviral action of silver nanoparticles against HIV-1

In Vitro Antiviral Activity of Cinnamomum cassia and Its Nanoparticles Against H7N3 Influenza A Virus

Inhibition effect of silver nanoparticles on herpes simplex virus 2

Antiviral activity of mycosynthesized silver nanoparticles against herpes simplex virus and human parainfluenza virus type 3

Tannic acid modified silver nanoparticles show antiviral activity in herpes simplex virus type 2 infection

GAG mimetic functionalised solid and mesoporous silica nanoparticles as viral entry inhibitors of herpes simplex type 1 and type 2 viruses

Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication

Polyphosphonium-oligochitosans decorated with nanosilver as new prospective inhibitors for common human enteric viruses

Glycofullerenes inhibit viral infection

Synthesis of giant globular multivalent glycofullerenes as potent inhibitors in a model of Ebola virus infection

Antiviral activity of self-assembled glycodendro[60]fullerene monoadducts

Mannose-binding lectin binds to Ebola and Marburg envelope glycoproteins, resulting in blocking of virus interaction with DC-SIGN and complement-mediated virus neutralization

Norovirus and histo-blood group antigens: demonstration of a wide spectrum of strain specificities and classification of two major binding groups among multiple binding patterns

Impair Foot-and-Mouth Disease Virus Replication

Delivery of drugs, proteins, and nucleic acids using inorganic nanoparticles

Fullerene Derivatives Strongly Inhibit HIV-1 Replication by Affecting Virus Maturation without Impairing Protease Activity

Silver nanoparticles impair Peste des petits ruminants virus replication

Biological activity of green-synthesized silver nanoparticles depends on the applied natural extracts: a comprehensive study

Carbon dots as inhibitors of virus by activation of type I interferon response

Reactive Oxygen Species-Regulating Polymersome as an Antiviral Agent against Influenza Virus

Viral exploitation of the MEK/ERK pathway -A tale of vaccinia virus and other viruses

Light-activated nanotube-porphyrin conjugates as effective antiviral agents

Antiviral Activity of Graphene Oxide: How Sharp Edged Structure and Charge Matter

Interaction of titanium dioxide nanoparticles with influenza virus

Nanocomposites against Non-Enveloped and Enveloped Viruses

Inactivation of MS2 bacteriophage by titanium dioxide nanoparticles in the presence of quartz sand with and without ambient light

Simple route to enhanced photocatalytic activity of p25 titanium dioxide nanoparticles by silica addition

Antiviral properties of silver nanoparticles on a magnetic hybrid colloid

Cytotoxicity and antiviral activity of electrochemical -synthesized silver nanoparticles against poliovirus

Antiviral Activity of Gold/Copper Sulfide Core/Shell Nanoparticles against Human Norovirus Virus-Like Particles

A look behind closed doors: interaction of persistent viruses with dendritic cells

Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns

Strategies for designing and monitoring malaria vaccines targeting diverse antigens

Lipid nanocapsule as vaccine carriers for his-tagged proteins: evaluation of antigen-specific immune responses to HIV I His-Gag p41 and systemic inflammatory responses

Skin dendritic cell targeting via microneedle arrays laden with antigen-encapsulated poly-D,L-lactide-co-glycolide nanoparticles induces efficient antitumor and antiviral immune responses

Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development

Clinical Applications of Virus-like Particles: Opportunities and Challenges

Exploiting virus-like particles as innovative vaccines against emerging viral infections

Virus-like particles as immunogens

HPV6b virus like particles are potent immunogens without adjuvant in man

Infections, Vaccines and Autoimmunity: A Multiple Sclerosis Perspective. Vaccines (Basel)

Hepatitis E vaccine development: a 14 year odyssey

Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines

Biodegradable nanoparticle delivery of inactivated swine influenza virus vaccine provides heterologous cell-mediated immune response in pigs

Immunization against HTLV-I with chitosan and tri-methylchitosan nanoparticles loaded with recombinant env23 and J o u r n a l P r e -p r o o f env13 antigens of envelope protein gp46

Synthetic vaccine nanoparticles target to lymph node triggering enhanced innate and adaptive antitumor immunity

Biodegradable Polymeric Nanoparticles-Based Vaccine Adjuvants for Lymph Nodes Targeting

Antigen-Loaded Upconversion Nanoparticles for Dendritic Cell Stimulation, Tracking, and Vaccination in Dendritic Cell-Based Immunotherapy

In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles

Exploiting lymphatic transport and complement activation in nanoparticle vaccines

Cross-presentation by dendritic cells

Biomimetic protein nanoparticles facilitate enhanced dendritic cell activation and cross-presentation

Induction of endoplasmic reticulum-endosome fusion for antigen cross-presentation induced by poly (gamma-glutamic acid) nanoparticles

Biomineralization improves the thermostability of foot-and-mouth disease virus-like particles and the protective immune response induced

The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors

Pattern recognition receptors in innate immunity, host defense, and immunopathology

ANGPTL8 negatively regulates NF-kappaB activation by facilitating selective autophagic degradation of IKKgamma

USP15 potentiates NF-kappaB activation by differentially stabilizing TAB2 and TAB3

Induction of Potent Antigen-specific Cytotoxic T Cell Response by PLGA-nanoparticles Containing Antigen and TLR Agonist

Generation of effector memory T cell-based mucosal and systemic immunity with pulmonary nanoparticle vaccination

Preconceptual Zika virus asymptomatic infection protects against secondary prenatal infection

Hepatitis B vaccine and the need for a booster dose after primary vaccination

Association between Haemagglutination inhibiting antibodies and protection against clade 6B viruses in

Antibody responses to vaccination among South African HIV-exposed and unexposed uninfected infants during the first 2 years of life

Role of nanoscale antigen organization on B-cell activation probed using DNA origami

Early BCR Events and Antigen Capture, Processing, and Loading on MHC

Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle

Virus-like particles in vaccine development

Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV

Gold nanoparticle-adjuvanted S protein induces a strong antigen-specific IgG response against severe acute respiratory syndrome-related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in lungs

Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus

Viromimetic STING Agonist-Loaded Hollow Polymeric Nanoparticles for Safe and Effective Vaccination against Middle East Respiratory Syndrome Coronavirus

Nanotechnology for COVID-19: Therapeutics and Vaccine Research

The COVID-19 vaccine development landscape

Nanoparticle formulated vaccines: opportunities and challenges

mRNA vaccine delivery using lipid nanoparticles

Delivery materials for siRNA therapeutics

Evolution of the COVID-19 vaccine development landscape

Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies

Broadly Neutralizing Antibodies for HIV-1 Prevention or Immunotherapy

Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge

Polyvalent vaccine approaches to combat HIV-1 diversity

HIV-1 neutralizing antibodies induced by native-like envelope trimers

Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity

Nanoparticles decorated with viral antigens are more immunogenic at low surface density

Inactivated influenza virus vaccines: the future of TIV and QIV

Local and systemic immune response in nursing-home elderly following intranasal or intramuscular immunization with inactivated influenza vaccine

Induction of mucosal immunity through systemic immunization: Phantom or reality?

Rabbit nasal immunization against influenza by dry-powder form of chitosan nanospheres encapsulated with influenza whole virus and adjuvants

A Nanoparticle-Poly(I:C)

Combination Adjuvant Enhances the Breadth of the Immune Response to Inactivated Influenza Virus Vaccine in Pigs. Vaccines (Basel)

Characterization of Immune Responses to an Inactivated Avian Influenza Virus Vaccine Adjuvanted with Nanoparticles Containing CpG ODN

Foot-and-mouth disease virus: Prospects for using knowledge of virus biology to improve control of this continuing global threat

Potency of a Scalable Nanoparticulate Subunit Vaccine

Hollow mesoporous silica nanoparticles as delivery vehicle of foot-and-mouth disease virus-like particles induce persistent immune responses in guinea pigs

Safe Staphylococcal Platform for the Development of Multivalent Nanoscale Vesicles against Viral Infections

Precisely Molded Nanoparticle Displaying DENV-E Proteins Induces Robust Serotype-Specific Neutralizing Antibody Responses

A novel dengue virus serotype-2 nanovaccine induces robust humoral and cell-mediated immunity in mice

Immunogenic Properties of a BCG Adjuvanted Chitosan Nanoparticle-Based Dengue Vaccine in Human Dendritic Cells

Responses of primary human nasal epithelial cells to EDIII-DENV stimulation: the first step to intranasal dengue vaccination

Gold nanoparticles as a vaccine platform: influence of size and shape on immunological responses in vitro and in vivo

Interrogation of Antigen Display on Individual Vaccine Nanoparticles for Achieving Neutralizing Antibody Responses against Hepatitis C Virus

Rational Design of Hybrid Peptides: A Novel Drug Design Approach

Salvation of the fallen angel: Reactivating mutant p53

Risk Assessment and Risk Minimization in Nanomedicine: A Need for Predictive, Alternative, and 3Rs Strategies

Breaking Down the Barriers to Precision Cancer Nanomedicine

Purified coronavirus J o u r n a l P r e -p r o o f spike protein nanoparticles induce coronavirus neutralizing antibodies in mice

MERS-CoV spike nanoparticles protect mice from MERS-CoV infection

Co-Delivery of M2e Virus-Like Particles with Influenza Split Vaccine to the Skin Using Microneedles Enhances the Efficacy of Cross Protection

We sincerely appreciate the investigators and authors who have contributed to this field and apologize that we could not discuss and cite all of them in this review due to space limitations. This work was supported by the Natural Science Foundation of China 

H7N3 Blocking the function of viral hemagglutinin, leading to the hindered viral entry [41] AgNPs HSV-2 Interacting with sulfhydryl group of membrane glycoproteins, thus preventing viral internalization [42] Tannic acid functionalized AgNPs J o u r n a l P r e -p r o o f